US$ 24.03
is bpc 157 available in canada BPC-157 – Toronto Peptides (PC) 2025 New Bpc-157 Peptide Capsules,
Description
WADA Prohibition The World Anti-Doping Agency explicitly prohibits AOD-9604 for competitive athletes: Listed under Section S0 (Non-Approved Substances) and S2.2.3 (Growth Hormone Fragments) Prohibited at all times (both in-competition and out-of-competition) No Therapeutic Use Exemptions (TUEs) available Detection methods developed and implemented in anti-doping laboratories worldwide WADAs 2013 statement clarified that AOD-9604 is a substance still under pre-clinical and clinical development and has not been approved for therapeutic use by any government health authority in the world. Research Classification: AOD-9604 is available only for laboratory research use

The exact frequency will depend on how your body responds to the treatment and the underlying cause of your deficiency

Most activity occurs in areas with high fat concentration like the abdomen and thighs

This product is sold strictly for research use only (RUO)

Regulatory watch Last reviewed Jul 1, 2026 Next review Jul 29, 2026 Evidence snapshot AOD-9604 was developed by Metabolic Pharmaceuticals (Australia) as a modified C-terminal fragment (residues 177-191) of human growth hormone, designed to retain lipolytic activity without growth-promoting effects

2023;95(10):e29137
